



AiCuris

Anti-infective Cures



AiCubator

**A new way of
collaboration in the
anti-infective area**

Creating value together

September 2023



FORWARD LOOKING STATEMENTS

Disclaimer

Certain information set forth in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in

development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) Future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

The reader is cautioned not to place undue reliance on forward-looking statements.

THE ANTI-INFECTIVE FIELD IS IN AN URGENT NEED FOR NEW HIGH-QUALITY PRODUCTS, BUT MANY BRILLIANT IDEAS DO NOT DEVELOP FURTHER



- **Joint effort** to deliver anti-infectives to patients in need
- **Bridge the gap** between early discovery and clinical development
- **Synergize** by bringing together complementary expertise
- **Leverage innovative approaches** with AiCuris' longstanding competence in anti-infectives and proven development capabilities


THE AICUBATOR PRINCIPLE

an open innovation approach to grow extraordinary anti-infectives projects



THE AICUBATOR PRINCIPLE

an open innovation approach to grow extraordinary anti-infectives projects



WHAT ARE WE OFFERING AND WHO ARE WE LOOKING FOR?

Which projects are we looking for?

- Academic research groups or early start-ups working on drug discovery projects for the treatment of viral infections in immunocompromised patients
- Indications:
 - BK virus
 - Adenovirus
 - Other viruses

Minimal requirements

- Non-cytotoxic hits or leads with in vitro activity
- Academic group or early start-up company

What does AiCubator offer?



- First-hand support from experienced interdisciplinary expert team covering scientific as well as business aspects, market positioning
- Access to AiCubator business and R&D network
- €10,000 financial support

WHY AICUBATOR?

Creating value together

AiCubator is a corporate incubator from AiCuris that gives residents the possibility to:


- Profit from our experience to overcome the pitfalls and hurdles
- View your project from a business and financial perspective to increase its value for investors
- Establish a trustful long-term partnership with AiCuris




Get first-hand guidance to transform your groundbreaking discovery into innovative medicine to fight infectious diseases of patients in need.

AICUBATOR CALL FROM FIRST OCTOBER TO 31ST DECEMBER 2023 RESULTS TO BE PUBLISHED IN APRIL 2024

CALL TO ACTION: apply until 31st December



Further information and the application form can be accessed on the website: www.aicubator.eu or by e-mail to aicubator@aicuris.com



AiCuris

Anti-infective Cures

AiCuris Anti-infective Cures AG

Friedrich-Ebert-Str. 475 / Building 302

42117 Wuppertal Germany

T: +49 (0)202 317 63 - 0

info@aicuris.com

www.aicuris.com